EurekaBio

Executive Summary

EurekaBio, founded in 2020 and headquartered in Shenzhen, China, is a private biotechnology company developing enabling technologies and platforms for the cell and gene therapy (CGT) industry. The company addresses critical manufacturing bottlenecks, particularly in viral vector production and cell processing, with its core technologies including the EuLV™ stable lentiviral vector production system and automated cell therapy manufacturing platforms. With $40 million raised to date, EurekaBio is positioned to support the rapidly growing CGT market by reducing costs and improving scalability of therapy production. The company operates in the oncology domain and aims to accelerate the development and commercialization of advanced therapies through its innovative solutions. The CGT manufacturing market is experiencing robust growth, driven by increasing approvals and pipeline expansion. EurekaBio's technologies offer significant advantages in yield, consistency, and automation, addressing key challenges faced by therapy developers. As the company continues to scale its operations and forge partnerships with biopharma firms, it is well-positioned to capture market share. Near-term focus includes commercializing the EuLV system and expanding its automated platform offerings. Given the strong demand for cost-effective manufacturing solutions, EurekaBio represents a promising investment opportunity in the CGT supply chain.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of EuLV™ stable lentiviral vector production system80% success
• Q4 2026Strategic partnership with a top-tier biopharma for cell therapy manufacturing60% success
• H1 2027Series B or later-stage funding round to support scale-up70% success